Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

Figure 1

Characterization of HER2 fusion monoclonal antibody (mAb). (A) Structure of HER2 fusion mAb. C', carboxyl-terminus; C region, constant region; ECD, extracellular domain (amino acid 22-653); N', amino-terminus; V region, variable region. (B) Fusion mAb (DEC-HER2 or Ctrl Ig-HER2) was produced by transient transfection of 293T cells with the appropriate vector and purified on a protein G column. Imperial protein staining (left panel) and Western blotting of the fusion mAb are shown, and the anti-mouse IgG1-HRP (αmIgG) and anti-HER2-Biotin/SAv-HRP (αHER2) antibodies are indicated below the figures. Lane 1: empty DEC mAb; lane 2: DEC-HER2 mAb; lane 3: Ctrl Ig-HER2 mAb. M, molecular weight standards (in kilodaltons). (C) Fluorescence-activated cell sorting staining data show the binding capacity of graded doses (0, 0.05, 0.5, and 5 μg/mL) of the indicated fusion mAb to the DEC or neomycin (Neo) stably transfected CHO cells. Binding was detected by fluorescence-labeled secondary antibody specific for mouse IgG1 or HER2 antigen. CHO, Chinese hamster ovary; HER, human epidermal growth factor receptor; Ig, immunoglobulin.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us